Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck

NCT01237483 is registered in ClinicalTrials.gov with Groupe Oncologie Radiotherapie Tete et Cou as lead sponsor.

NCT NCT01237483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01237483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck
Lead sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
July 5, 2016
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer squamous cell